Pathophysiology
Lactotroph adenoma autonomously secretes prolactin, suppressing GnRH pulsatility and thus LH/FSH - hypogonadotrophic hypogonadism. Stalk-effect hyperprolactinaemia occurs when non-secreting sellar masses interrupt dopaminergic inhibition.
Sources: Endocrine Society CPG Hyperprolactinemia (J Clin Endocrinol Metab 2011;96:273); Pituitary Society Consensus on Prolactinomas (Lancet Diabetes Endocrinol 2023;11:722)
Clinical presentation
Women: oligomenorrhoea/amenorrhoea, infertility, galactorrhoea. Men: erectile dysfunction, reduced libido, gynaecomastia, infertility. Macroadenoma: headache, visual field defects, hypopituitarism.
Sources: Endocrine Society CPG Hyperprolactinemia (J Clin Endocrinol Metab 2011;96:273); Pituitary Society Consensus on Prolactinomas (Lancet Diabetes Endocrinol 2023;11:722)
Diagnosis
Confirm elevated prolactin, exclude pregnancy, primary hypothyroidism, renal failure, and drugs (antipsychotics, metoclopramide, opioids, oestrogens). Prolactin >200 mcg/L strongly suggests prolactinoma. MRI pituitary defines size; formal visual fields for macroadenomas. Dilute samples to exclude hook effect.
Sources: Endocrine Society CPG Hyperprolactinemia (J Clin Endocrinol Metab 2011;96:273); Pituitary Society Consensus on Prolactinomas (Lancet Diabetes Endocrinol 2023;11:722)
Management
Dopamine agonists first-line - cabergoline preferred (better tolerated, shrinks tumour in >80%). Transsphenoidal surgery for intolerance, resistance, or CSF leak. Radiotherapy reserved for refractory disease.
Sources: Endocrine Society CPG Hyperprolactinemia (J Clin Endocrinol Metab 2011;96:273); Pituitary Society Consensus on Prolactinomas (Lancet Diabetes Endocrinol 2023;11:722)







